Evidence map›Paper›PMID 33939308›Full record

ArticleThoracic cancer2021

CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.

Keigo Koda, Mikio Toyoshima, Shusuke Yazawa, Atsuki Fukada, Haruhiko Sugimura, Takafumi Suda

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Keigo KodaDepartment of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan.
Mikio ToyoshimaDepartment of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan.ORCID 0000-0002-8349-0142
Shusuke YazawaDepartment of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan.
Atsuki FukadaDepartment of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan.
Haruhiko SugimuraDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Takafumi SudaSecond Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hamamatsu Rosai Hospital · JPHamamatsu University · JPHamamatsu University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and peripheral atypical lymphocytosis appeared after 33 cycles of second-line treatment with nivolumab, and a specimen obtained by left inguinal lymph node biopsy showed peripheral T cell lymphoma (PTCL), not otherwise specified. Lymphoma cells expressed CD3+, CD8+, and CD56+, but not CD4+ or PD-1. Despite systemic chemotherapy with cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone, the patient died of PTCL 864 days after the initial visit. The possible relationship between treatment with immune checkpoint inhibitors (ICIs) and PTCL development is discussed here.

Indexed as

Adenocarcinoma of LungCD8-Positive T-LymphocytesHumansImmune Checkpoint InhibitorsLung NeoplasmsLymphoma, T-Cell, PeripheralMaleMiddle AgedNivolumabImmune Checkpoint InhibitorsNivolumabimmune checkpoint inhibitorlung cancernivolumabT cell lymphoma

Identifiers

PMID33939308
PMCPMC8169286
OpenAlexW3158646183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.